Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy. METHODS: In this prospective-retrospective analysis, we assessed the efficacy and safety of panitumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as compared with FOLFOX4 alone, according to RAS (KRAS or NRAS) or BRAF mutation status. A total of 639 patients who had metastatic colorectal cancer without KRAS mutations in exon 2 had results for at least one of the following: KRAS exon 3 or 4; NRAS exon 2, 3, or 4; or BRAF exon 15. The overall rate of ascertainment of RAS status was 90%. RESULTS: Among 512 patients without RAS mutations, progression-free survival was 10.1 months with panitumumab-FOLFOX4 versus 7.9 months with FOLFOX4 alone (hazard ratio for progression or death with combination therapy, 0.72; 95% confidence interval [CI], 0.58 to 0.90; P=0.004). Overall survival was 26.0 months in the panitumumab-FOLFOX4 group versus 20.2 months in the FOLFOX4-alone group (hazard ratio for death, 0.78; 95% CI, 0.62 to 0.99; P=0.04). A total of 108 patients (17%) with nonmutated KRAS exon 2 had other RAS mutations. These mutations were associated with inferior progression-free survival and overall survival with panitumumab-FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2. BRAF mutations were a negative prognostic factor. No new safety signals were identified. CONCLUSIONS: Additional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4. In patients who had metastatic colorectal cancer without RAS mutations, improvements in overall survival were observed with panitumumab-FOLFOX4 therapy. (Funded by Amgen and others; PRIME ClinicalTrials.gov number, NCT00364013.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consistent with BRAFV600E mutation, signaling independent of upstream input, anti-EGFR therapy is not useful in patients with BRAFV600E tumors as single agents [93] or in combination with chemotherapy [94].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [94]
In the citing paper
“Additional rare mutations of KRAS, as well as mutations of NRAS, have been associated with primary resistance to treatment.”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [35]
In the citing paper
“Further analysis of molecular subgroups in this study showed that adding panitumumab significantly improved mPFS and mOS in the non-mutated KRAS group but was ineffective in patients with KRAS non-exon 2 mutations [15].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [15]
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
In the citing paper
“The most frequently detected mutations in codons 12 and 13—namely G12V (incidence: 20–25%), G12S (5–7%), G12R (3–5%), G12A (3–5%), and G13D (15–20%)—are also clinically relevant, with their prevalence varying by tumor type [16,17,18].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 5×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
InfluentialSelf-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 4×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
InfluentialSelf-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 3×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
Self-citationVan Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citationDouillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809 · cited 2×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
Self-citationWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Self-citationRas oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 3×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005
Self-citation
Research works printed but not linked: 2
- Wojcik P, 2008, Pol J Pathol, 59, 93
- Yuen ST, 2002, Cancer Res, 62, 6451
Cited by
Items 601–700 of 1,008
Kim, Y. J., Chambers, A. G., Cecchi, F., & Hembrough, T. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.04.022 · Cited by 34
Furuse, J., Kurata, T., Okano, N., Fujisaka, Y., Naruge, D., Shimizu, T., Kitamura, H., Iwasa, T., Nagashima, F., & Nakagawa, K. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3618-4 · Cited by 34
Linden, C. V., & Corbet, C. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.016 · Cited by 34
Matsumoto, A., Shimada, Y., Nakano, M., Oyanagi, H., Tajima, Y., Nakano, M., Kameyama, H., Hirose, Y., Ichikawa, H., Nagahashi, M., et al. (2020) · Oncology Reports · doi:10.3892/or.2020.7561 · Cited by 37
“Multiple studies have revealed that the BRAF V600E mutation is associated with poor prognosis in metastatic CRC (38,39), as well as poor response to anti-EGFR therapy in later lines of therapy (40,41).”
BackgroundTargeting KRAS in Colorectal Cancer
Wang, C., & Fakih, M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01022-0 · Cited by 37
Nakajima, H., Kotani, D., Bando, H., Kato, T., Oki, E., Shinozaki, E., Sunakawa, Y., Yamazaki, K., Yuki, S., Nakamura, Y., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08395-2 · Cited by 37
“Anti-epidermal growth factor receptor (EGFR), monoclonal antibodies (mAbs), panitumumab, and cetuximab are key standard drugs for patients with metastatic colorectal cancer (mCRC) with RAS wild-type tumors [1–4], achieving a median overall survival (OS) of approximately 30 months [1, 2, 5, 6].”
BackgroundPfeiffer, P., Sorbye, H., Qvortrup, C., Karlberg, M., Kersten, C., Vistisen, K. K., Lindh, B., Bjerregaard, J. K., & Glimelius, B. L. G. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.03.002 · Cited by 36
“The cumulative oxaliplatindose was 601 mg/m2 (IQR50 532-680).”
InfluentialKwok, H. F., Zhang, S., McCrudden, C. M., Chen, M., & Lin, Y. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s80518 · Cited by 37
“Recent advances in molecular testing have led to the identification of a subgroup of patients, whose tumors have KRas or NRas mutations, for whom anti-EGFR antibodies, including cetuximab and panitumumab, are not a viable treatment option.(24,34) However, no advances to identify suitable (or unsuitable) candidates for…”
Kothari, N., Schell, M. J., Teer, J. K., Yeatman, T. J., Shibata, D., & Kim, R. D. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202405 · Cited by 34
Perfusion CT imaging of colorectal cancer
Goh, V., & Glynne‐Jones, R. (2014) · British Journal of Radiology · doi:10.1259/bjr.20130811 · Cited by 40
on behalf of the BIG-RENAPE Working Group, Passot, G., Kim, B. J., Gléhen, O., Mehran, R. J., Kopetz, S., Goèré, D., Overman, M. J., Pocard, M. D., Marchal, F., et al. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-6141-7 · Cited by 38
“However, given the low rate of non-exon 2 KRAS and NRAS mutations,\ 10% of patients in this study would be affected by expanded RAS testing.(32)”
BackgroundTargeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review
DeStefanis, R. A., Kratz, J. D., Emmerich, P. B., & Deming, D. A. (2019) · Current Colorectal Cancer Reports · doi:10.1007/s11888-019-00430-6 · Cited by 42
Price, T., Ang, A., Boedigheimer, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Satya Suresh, A., Thomas, A., Tjulandin, S., et al. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1798695 · Cited by 33
Self-citationElez, E., Hendlisz, A., Delaunoit, T., Sastre, J., Cervantes, A., Varea, R., Chao, G., Wallin, J., & Tabernero, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.480 · Cited by 33
“Further investigation is required to assess whether mutations at other RAS loci are negative predictors of efficacy for necitumumab in combination with a FOLFOX regimen, as has been reported for cetuximab and panitumumab (Douillard et al, 2013; Bokemeyer et al, 2015).”
BackgroundSelf-citationPharmacogenetics and pharmacogenomics as tools in cancer therapy
Rodríguez‐Vicente, A. E., Lumbreras, E., Hernández-Sánchez, J. M., Martín, M., Calles, A., López-Otín, C., Martín‐Algarra, S., Páez, D., & Tarón, M. (2016) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2015-0042 · Cited by 40
“However, these mutations have not shown a clear predictive effect related to anti-EGRF therapies in randomized clinical trials such as the PRIME study [49], and until now, no changes in the label by any regulatory authority have been made.”
BackgroundMacarulla, T., Cervantes, A., Tabernero, J., Roselló, S., Van Cutsem, E., Tejpar, S., Prenen, H., Martinelli, E., Troiani, T., Laffranchi, B., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.144 · Cited by 33
“…combination therapy second-line treatment British Journal of Cancer (2015) 112, 1874–1881 | doi: 10.1038/bjc.2015.144 1874 www.bjcancer.com |DOI:10.1038/bjc.2015.144 (Bokemeyer et al, 2009, 2012; Van Cutsem et al, 2009, 2011; De Roock et al, 2010; Douillard et al, 2010, 2013; Ye et al, 2013).”
Self-citationDevelopment of circulating tumour DNA analysis for gastrointestinal cancers
Nakamura, Y., & Shitara, K. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000600 · Cited by 34
KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas
Martianov, A. S., Mitiushkina, N. V., Ershova, A. N., Мартыненко, Д. Е., Бубнов, М. Г., Amankwah, P. S., Yanus, G. A., Алексахина, С. Н., Tiurin, V. I., Venina, A. R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054868 · Cited by 37
“This is an important finding, given that the anti-EGFR therapeutic antibodies cetuximab and panitumumab are contraindicated for RAS-mutated CRCs and may even boost tumor progression in this category of patients [5,6].”
BackgroundJang, S.-J., Hong, M. E., Shin, M. K., Kim, B. C., Shin, H.-S., Yu, E., Hong, S., Kim, J., Chun, S., Kim, T., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.01.010 · Cited by 34
Taniguchi, H., Okamoto, W., Muro, K., Akagi, K., Hara, H., Nishina, T., Kajiwara, T., Denda, T., Hironaka, S., Kudo, T., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.10.004 · Cited by 33
Lee, M. S., & Kopetz, S. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.05.006 · Cited by 41
“01 for OS), indicating that there are different treatment effects in those who are RAS-unmutated in all loci compared with those who have a RAS mutation in a locus other than exon 2.(6)”
BackgroundBelardinilli, F., Capalbo, C., Buffone, A., Petroni, M., Colicchia, V., Ferraro, S., Zani, M., Nicolussi, A., D'inzeo, S., Coppa, A., et al. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.04.003 · Cited by 34
“Furthermore, the predictive role of mutations in other members of the RAS– BRAF–MEK and PI3K–AKT pathways remains controversial [6,8].”
BackgroundNew therapeutic strategies for BRAF mutant colorectal cancers.
Corcoran, R. B. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.076 · Cited by 35
Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer
Haas, M., Ormanns, S., Baechmann, S., Remold, A., Kruger, S., Westphalen, C. B., Siveke, J. T., Wenzel, P., Schlitter, A. M., Esposito, I., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.115 · Cited by 35
“Compared with colorectal cancer, where other RASmutations amount to approximately 17% of mutations in KRAS exon 2 wild-type patients (Douillard et al, 2013), these more rare mutations seem to have a secondary role in PC.”
BackgroundTikhonova, I. A., Huxley, N., Snowsill, T., Crathorne, L., Varley‐Campbell, J., Napier, M., & Hoyle, M. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0630-9 · Cited by 34
“2 months for patients treated with FOLFOX alone [30], with the difference in survival being statistically significant.”
BackgroundSchmoll, H., Arnold, D., de Gramont, A., Ducreux, M. P., Grothey, A. F., O'Dwyer, P. J., Cutsem, E. V., Hermann, F., Bosanac, I., Bendahmane, B., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2632-6 · Cited by 34
Self-citationYang, Q., Huo, S., Sui, Y., Du, Z., Zhao, H., Liu, Y., Li, W., Wan, X., Liu, T., & Zhang, G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00487 · Cited by 32
“The commonmutation site ofNRAS gene is located in exons 2, 3, and 4 (6).”
BackgroundResultLiquid biopsy to monitor melanoma patients
Gaiser, M. R., von Bubnoff, N. C. C., Gebhardt, C., & Utikal, J. S. (2018) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13461 · Cited by 37
Modest, D. P., Rivera, F., Bachet, J., de Braud, F., Pietrantonio, F., Koukakis, R., Demonty, G., & Douillard, J.-Y. (2019) · International Journal of Cancer · doi:10.1002/ijc.32110 · Cited by 32
“Any 7 (13) 4 (10) 53 (13) 1 (3) 4 (13) 18 (17)”
InfluentialSelf-citationUpdate on systemic therapy for colorectal cancer: biologics take sides
Gbolahan, O. B., & O’Neil, B. H. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.01.12 · Cited by 34
BTK inhibitors synergise with 5‐FU to treat drug‐resistant TP53‐null colon cancers
Lavitrano, M., Ianzano, L., Bonomo, S., Cialdella, A., Cerrito, M. G., Pisano, F., Missaglia, C., Giovannoni, R., Romano, G., McLean, C. M., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5347 · Cited by 32
Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Bteich, F., Mohammadi, M., Li, T., Bhat, M. A., Sofianidi, A. A., Wei, N., & Kuang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512030 · Cited by 36
Granata, V., Fusco, R., Muzio, F. D., Brunese, M. C., Setola, S. V., Ottaiano, A., Cardone, C., Avallone, A., Patrone, R., Pradella, S., et al. (2023) · La radiologia medica · doi:10.1007/s11547-023-01710-w · Cited by 37
“In addition to surgical approach, mutational RAS status is correlated to anti-EGFR mAbs (cetuximab and panitumumab) response [169–171.”
BackgroundRandle, R. W., Doud, A. N., Levine, E. A., Clark, C. J., Swett, K. R., Shen, P., Stewart, J. H., & Votanopoulos, K. I. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3987-9 · Cited by 32
“Although modern chemotherapy has resulted in survival outcomes of up to 23–26 months for patients with stage IV colon cancer, we measured survival from the date of surgery, which followed chemotherapy as opposed to the date of diagnosis and initiation of chemotherapy.(10,11) The survival benefit provided by CRS/HIPEC…”
A framework for genomic biomarker actionability and its use in clinical decision making
Vidwans, S. J., Turski, M. L., Jankú, F., Garrido‐Laguna, I., Munoz, J., Schwab, R. B., Subbiah, V., Rodon, J. A., & Kurzrock, R. (2014) · Oncoscience · doi:10.18632/oncoscience.90 · Cited by 33
“For example, standard treatment guidelines recommend KRAS and NRAS testing for colorectal cancer patients and that patients with KRAS- and NRAS-mutated colorectal cancer not be treated with epidermal growth factor receptor inhibitors such as cetuximab and panitumumab [39-44] .”
BackgroundAmikura, K., Akagi, K., Ogura, T., Takahashi, A., & Sakamoto, H. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24910 · Cited by 34
“The results of all-RAS mutation analyses have been reported in large-scale clinical trials on the effects of the anti-EGFR antibody therapy.(6,23,28) These trials resulted that the additional use of antiEGFR antibody therapy induced a significant benefit in metastatic CRC patients with all-RAS wild-type.”
BackgroundResultSex Difference of Colon Adenoma Pathway and Colorectal Carcinogenesis
Choi, Y., & Kim, N. (2023) · The World Journal of Men s Health · doi:10.5534/wjmh.230085 · Cited by 39
“More than one-third of CRCs carry mutations in exon 2 of KRAS, and an additional 15% carry mutations in exons 3 and 4 of KRAS and in exons 2, 3, and 4 of NRAS, that predict resistance to anti-EGFR antibody therapy [154,155,157,158].”
BackgroundAdvances and new perspectives in the treatment of metastatic colon cancer
Recondo, G. (2014) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v6.i7.211 · Cited by 34
Chevrier, S., Arnould, L., Ghiringhelli, F., Coudert, B. P., Fumoleau, P., & Boidot, R. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2528 · Cited by 31
Maughan, T., Meade, A. M., Adams, R., Richman, S. D., Butler, R., Fisher, D. J., Wilson, R. H., Jasani, B., Taylor, G. R., Williams, G. T., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.182 · Cited by 32
“with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?”
BackgroundZhou, M.-Y., Yu, P., Qu, J., Chen, Y., Zhou, Y., Fu, L., & Zhang, J. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000452551 · Cited by 32
Geißler, A.-L., Geissler, M., Kottmann, D., Lutz, L., Fichter, C. D., Fritsch, R., Weddeling, B., Makowiec, F., Werner, M., & Laßmann, S. (2017) · Oncotarget · doi:10.18632/oncotarget.15211 · Cited by 32
“Of the 8/25 patients with RAS mutations 5/8 showed progressive disease, for 2/8 no information about response rate was available, further underlying the concept of comprehensive RAS testing [7, 50].”
BackgroundTashiro, T., Okuyama, H., Endo, H., Kawada, K., Ashida, Y., Ohue, M., Sakai, Y., & Inoue, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174151 · Cited by 33
Byun, J. H., Ahn, J. B., Kim, S. Y., Kang, J. H., Zang, D. Y., Kang, S. Y., Kang, M. J., Shim, B. Y., Baek, S. K., Kim, B.-S., et al. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.348 · Cited by 35
“Monoclonal antibody inhibition of the epidermal growth factor receptor (EGFR) cetuximab or panitumumab has also been associated with improved patient outcomes, but only in the absence of RAS gene mutations [11,12].”
BackgroundDufraing, K., Hertogh, G. D., Tack, V., Keppens, C., Dequeker, E. M. C., & van Krieken, J. H. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.03.003 · Cited by 31
“The reliability and accuracy of biomarker testing is essential for optimal patient care, and errors might lead to the denial of treatment to a patient who could have benefited from it or to the overuse of these expensive therapeutic agents, which can even cause major adverse events.(3) The selection of themost optimal…”
BackgroundGrassadonia, A., Marino, P. D., Ficorella, C., Cortellini, A., Cannita, K., Parisi, A., Gamucci, T., Zoratto, F., Vici, P., Barba, M., et al. (2019) · Journal of Cancer · doi:10.7150/jca.34550 · Cited by 36
“tumors not harboring mutations in exons 2, 3 and 4 of both KRAS and NRAS [8, 9].”
BackgroundInfluentialSastre, J., de la Orden, V., Martínez, A., Bando, I., Balbı́n, M., Bellosillo, B., Palanca, S., Peligros, M. I., Mediero-Valeros, B., Llovet, P., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.02.014 · Cited by 31
DRP1 Promotes BRAFV600E-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer
Padder, R. A., Bhat, Z. I., Ahmad, Z., Singh, N., & Husain, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.592130 · Cited by 36
“org 10 been known since recently that m-CRC with mutated RAS is resistant to anti-EGFR therapies (64, 65), and those with MSI phenotype are sensitive to immunotherapy (66, 67), but colorectal cancer with BRAF mutation/s is awaiting such a specific chemotherapeutic approach.”
BackgroundAntoniotti, C., Korn, W. M., Marmorino, F., Rossini, D., Lonardi, S., Masi, G., Randon, G., Conca, V., Boccaccino, A., Tomasello, G., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.037 · Cited by 37
Mazzoli, G., Cohen, R., Lonardi, S., Corti, F., Élez, E., Fakih, M., Jayachandran, P., Colle, R., Shah, A. T., Salati, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.044 · Cited by 34
Prognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon
Erstad, D. J., Tumusiime, G., & Cusack, J. C. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4706-x · Cited by 37
“Mutations other than exon 2 have also been shown to reduce response to panitumumab in metastatic disease.(79) For metastatic pulmonary disease, KRAS exon 2 mutation predicted higher risk of recurrence and a more diffuse pattern of metastasis.”
BackgroundHow to select the optimal treatment for first line metastatic colorectal cancer
Stein, A., & Bokemeyer, C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i4.899 · Cited by 33
KRAS mutations: Analytical considerations
Herreros‐Villanueva, M., Chen, C.-C., Yuan, S. F., Liu, T., & Er, T. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.049 · Cited by 35
“reported that additional RASmutations predicted a lack of response in patientswithmCRC who received panitumumab-FOLFOX4 [103].”
BackgroundState of Art of Cancer Pharmacogenomics in Latin American Populations
López‐Cortés, A., Guerrero, S. X., Redal, M. A., Alvarado, Á. T., & Quiñones, L. A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18060639 · Cited by 36
Siano, M., Molinari, F., Martin, V., Mach, N., Früh, M., Freguia, S., Corradino, I., Ghielmini, M. E. G., Frattini, M., & Espeli, V. G. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0069 · Cited by 31
“In colorectal cancer, the presence of KRAS mutation was predictive for lack of anti-EGFR antibody treatment benefit [7].”
BackgroundKim, S. Y., & Kim, T. W. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000634 · Cited by 35
Goldstein, D. A., & El‐Rayes, B. F. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0028 · Cited by 30
The possibility of clinical sequencing in the management of cancer
Kou, T., Kanai, M., Matsumoto, S., Okuno, Y., & Muto, M. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw018 · Cited by 32
Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment
Verdaguer, H., Saurí, T., & Macarulla, T. M. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.11.15 · Cited by 36
“Mutations in KRAS and NRAS are found in approximately 50% of advanced CRCs, with the majority of mutations involving KRAS exon 2 (90%) (5).”
BackgroundBattaglin, F., Dadduzio, V., Bergamo, F., Manai, C., Schirripa, M., Lonardi, S., Zagonel, V., & Loupakis, F. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356815 · Cited by 74
“lack of statistical power [35,45], however, two recent metaanalyses showed no outcome improvements both in terms of”
ResultDoll, S., KRIEGMAIR, M. C., Santos, A., Wierer, M., Coscia, F., Neil, H., Porubský, Š., Geyer, P. E., Mund, A., Nuhn, P., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12326 · Cited by 34
“However, EGFR-targeted therapy was not initiated because patients with similar KRAS mutations as our patient did not respond to therapy (Bokemeyer et al., 2015; Douillard et al., 2013).”
BackgroundClinical and Translational Research Challenges in Biliary Tract Cancers
Lamarca, Á., Frizziero, M., McNamara, M. G., & Valle, J. W. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200123090153 · Cited by 30
Cho, J., Kim, K., Kim, H. C., Lee, W. Y., Kang, W. K., Park, Y. S., & Ha, S. Y. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.10.024 · Cited by 33
BRAF Mutation and Its Importance in Colorectal Cancer
Luu, L., & Price, T. J. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82571 · Cited by 33
Wu, C., Wang, J., Lin, P., Liang, C.-A., Huang, C.-Y., Lien, H.-C., Chen, C., Chou, K.-J., & Su, Y. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102823 · Cited by 34
Current therapy of advanced colorectal cancer according to RAS/RAF mutational status
Lakatos, G., Köhne, C., & Bodoky, G. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09913-7 · Cited by 33
Self-citationPolívka, J., Windrichová, J., Pešta, M., Houfková, K., Řezáčková, H., Macanova, T., Vyčítal, O., Kučera, R., Slouka, D., & Topolčan, O. (2020) · Cancers · doi:10.3390/cancers12092434 · Cited by 30
Erve, I. V. ’., Greuter, M. J. E., Bolhuis, K., Vessies, D. C. L., Leal, A., Vink, G. R., van den Broek, D. A., Velculescu, V. E., Punt, C. J. A., Meijer, G. A., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.09.002 · Cited by 33
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
Puccini, A., Seeber, A., & Berger, M. D. (2022) · Cancers · doi:10.3390/cancers14194828 · Cited by 31
Li, L., Jiang, D., Liu, H., Guo, C., Zhao, R., Zhang, Q., Xu, C., Qin, Z., Feng, J., Liu, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37221-5 · Cited by 35
Tiam1 methylation by NSD2 promotes Rac1 signaling activation and colon cancer metastasis
Song, D., Hu, F., Huang, C., Lan, J., She, X., Zhao, C., Wu, H., Liu, A., Wu, Q., Chen, Y., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305684120 · Cited by 31
Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation
Rolle, A.-F. L., Chiu, T. K., Zeng, Z., Shia, J., Weiser, M. R., Paty, P. B., & Chiu, V. K. (2016) · Oncotarget · doi:10.18632/oncotarget.6818 · Cited by 36
Colling, R. T., Wang, L. M., & Soilleux, E. J. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204356 · Cited by 30
Improvements in Clinical Outcomes for BRAFV600E-Mutant Metastatic Colorectal Cancer
Morris, V. K., & Bekaii‐Saab, T. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3809 · Cited by 33
“Dysfunction of this pathway, including theRAS, RAF, and MEK kinases, leads to increased cell proliferation and survival by the disruption of apoptosis (7).”
ResultInfluentialBouchahda, M., Saffroy, R., Karaboué, A., Hamelin, J., Innominato, P. F., Saliba, F., Lévi, F., Bosselut, N., & Lemoine, A. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00400 · Cited by 33
Leto, S. M., Ferri, M., Sassi, F., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2550 · Cited by 30
“However, although response rates are clinically meaningful, anti-EGFR therapy only exceptionally leads todisease eradication, and patients ultimately recur (5).”
Chung, S., Chang, Y., Hsu, D. S., Hung, Y.-C., Lu, M.-L., Hung, Y., Chiang, N., Yeh, C., Hsiao, M., Soong, J., et al. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100856 · Cited by 33
Geng, Y., Zheng, X., Zhang, D., Wei, S., Feng, J., Wang, W., Zhang, L., Wu, C., & Hu, W. (2024) · Biology Direct · doi:10.1186/s13062-024-00478-x · Cited by 32
“The status of the RAS gene (wild/mutant type) is an effective molecular predictor of sensitivity to anti-EGFR therapy [4, 5].”
BackgroundInter- and intra-tumor profiling of multi-regional colon cancer and metastasis
Kogita, A., Yoshioka, Y., Sakai, K., Togashi, Y., Sogabe, S., Nakai, T., Okuno, K., & Nishio, K. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.064 · Cited by 29
“Patients with NRAS (Q61K), detected in P2-2, are also considered to be less sensitive to anti-EGFR antibodies [26,27].”
BackgroundKaczirek, K., Ciuleanu, T., Vrbanec, D., Márton, E., Messinger, D., Liegl‐Atzwanger, B., Wrba, F., Knittelfelder, R., Lindner, E., Zielinski, C. C., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.12.003 · Cited by 29
Somatic DNA mutation analysis in targeted therapy of solid tumours.
Yu, B., O'Toole, S. A., & Trent, R. J. (2015) · PubMed Central · doi:10.3978/j.issn.2224-4336.2015.04.04 · Cited by 33
Fernández‐Ruiz, M., García‐Campelo, R., Garrido-Castro, A. C., & Ruíz-Camps, I. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.12.027 · Cited by 29
Research progress on common adverse events caused by targeted therapy for colorectal cancer (Review)
Zhang, B., Fang, C., Deng, D., & Xia, L. (2018) · Oncology Letters · doi:10.3892/ol.2018.8651 · Cited by 33
“In comparison, targeted therapy is associated with improved compliance, decreased toxicity and fewer side effects in addition to improved prognosis (10,11).”
BackgroundNeerincx, M., Poel, D., Sie, D., van Grieken, N. C. T., Shankaraiah, R. C., van der Wolf, F. S. W., van Waesberghe, J. H. T. M., Burggraaf, J. D., Eijk, P. P., Verhoef, C. K., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201809 · Cited by 29
Ikoma, T., Shimokawa, M., Kotaka, M., Matsumoto, T., Nagai, H., Boku, S., Shibata, N., Yasui, H., & Satake, H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08271-z · Cited by 33
Agy, F. E., Bardai, S. E., Otmani, I. E., Benbrahim, Z., Karim, I. M. H., Mazaz, K., Benjelloun, E. B., Ousadden, A., Abkari, M. E., Ibrahimi, S. A., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248522 · Cited by 29
“Recently, mutations in KRAS outside exon 2 (KRAS exons 3,4) and in other downstream effectors of the EGFR signalling pathway, such as NRAS have been reported to be also associated with resistance to anti-EGFR monoclonal antibodies [8].”
BackgroundResultComprehensive tumor molecular profile analysis in clinical practice
Özdoğan, M., Papadopoulou, E., Τσούλος, Ν., Tsantikidi, A., Mariatou, V.-M., Tsaousis, G., Kapeni, E., Bourkoula, E., Fotiou, D. F., Kapetsis, G., et al. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-00952-9 · Cited by 30
“91%) carried a mutation in one of the RAS genes which are biomarkers of resistance to EGFR antibodies treatment [50, 51].”
Predictive and Prognostic Markers in the Treatment of Metastatic Colorectal Cancer (mCRC)
Stintzing, S., Stremitzer, S., Sebio, A., & Lenz, H. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.09.009 · Cited by 33
EGFR signaling in colorectal cancer: a clinical perspective
Frattini, M., Saletti, P., Molinari, F., & Dosso, S. D. (2015) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s49002 · Cited by 45
“Similar trends have been reported in the randomized Phase II OPUS trial, with an observed higher RR (57% versus 34%, P = 0.0027) in favor of cetuximab plus FOLFOX.”
InfluentialBekaii‐Saab, T., & Wu, C. S.-Y. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.01.001 · Cited by 30
“Recent data suggest that additional AS mutations (KRAS and NRAS) identified in tumors preiously classified as KRAS wild type may allow for further efinement of panitumumab use [33].”
BackgroundInfluentialAng, C., Miura, J. T., Gamblin, T. C., He, R., Xiu, J., Millis, S. Z., Gatalica, Z., Reddy, S. K., Yee, N. S., & Abou‐Alfa, G. K. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.24086 · Cited by 30
The renewed battle against RAS-mutant cancers
Zhang, F., & Cheong, J. K. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2155-8 · Cited by 32
Zheng, G., Tsai, H. K., Tseng, L., Illei, P. B., Gocke, C. D., Eshleman, J. R., Netto, G. J., & Lin, M. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw043 · Cited by 29
Favazza, L. A., Parseghian, C. M., Kaya, C., Nikiforova, M. N., Roy, S., Wald, A. I., Landau, M. S., Proksell, S. S., Dueker, J. M., Johnston, E. R., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0560-x · Cited by 30
Leiser, D., Medová, M., Mikami, K., Nisa, L., Stroka, D., Blaukat, A., Bladt, F., Aebersold, D. M., & Zimmer, Y. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.04.001 · Cited by 30
“…data published by Douillard et al., who demonstrated that mutations, other than those in KRAS exon 2, conferred resistance to EGFR inhibitors, and that the data could be used to improve the benefiterisk profile of panitumab-FOLFOX4 treatment in metastatic colorectal cancer (Douillard et al., 2013).”
BackgroundRAS testing in metastatic colorectal cancer: advances in Europe
van Krieken, J. H., Rouleau, É., Ligtenberg, M. J. L., Normanno, N., Patterson, S. D., & Jung, A. (2015) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-015-1876-7 · Cited by 29
“For example, 17 % of patients with tumors WT for KRAS codons 12 and 13 in the PRIME study (~10 % of patients overall) were found to have mutations in other KRAS codons and/or NRAS [14].”
InfluentialSelf-citationPotential biomarkers for anti-EGFR therapy in metastatic colorectal cancer
Yang, J., Li, S., Wang, B., Wu, Y., Chen, Z., Lv, M., Lin, Y., & Yang, J. (2016) · Tumor Biology · doi:10.1007/s13277-016-5140-9 · Cited by 30
“Because of the low incidence of BRAF mutations and the small sample size in each study, no significant differences were found in large randomized controlled studies [39, 49, 50].”
BackgroundVidal, J., Bellosillo, B., Vivas, C. S., Alfonso, P. G., Carrato, A., Cano, M. T., García‐Carbonero, R., Élez, E., Losa, F., Massutí, B., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz005 · Cited by 33
Self-citationZhou, J., Li, Q., & Cao, Y. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3665 · Cited by 29
“Because patients with RAS mutations were predicted to have a limited response to panitumumab (26), we further stratified the patients into either with or without panitumumab.”
BackgroundTherapeutic antibodies for precise cancer immunotherapy: current and future perspectives
Liu, L., & Chen, J. (2022) · Medical Review · doi:10.1515/mr-2022-0033 · Cited by 29
Metadata
- Authors
- Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., Rivera, F., Kocákova, I., Ruff, P., Błasińska-Morawiec, M., Šmakal, M., Canon, J. L., Rother, M., Williams, R., Rong, A., Wiezorek, J., Sidhu, R., & Patterson, S. D.
- Affiliations
- Institut de Cancérologie de l'Ouest (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-09-12
- Volume
- 369
- Issue
- 11
- Pages
- 1023-1034
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085633477
- Cited by
- 2,263
- References
- 31
- Citations by year
- 2026: 67 · 2025: 98 · 2024: 110 · 2023: 113 · 2022: 125 · 2021: 203 · 2020: 159 · 2019: 178 · 2018: 181 · 2017: 228 · 2016: 251 · 2015: 290 · 2014: 239 · 2013: 16
- FWCI
- 142.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- panitumumab, FOLFOX4, metastatic colorectal cancer, RAS mutations, KRAS exon 2, NRAS, BRAF mutation, anti-EGFR therapy, predictive biomarkers, progression-free survival, overall survival, oxaliplatin, 5-fluorouracil, leucovorin, treatment efficacy and safety, prognostic factors, combination chemotherapy
- MeSH terms
- Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Fluorouracil, Humans, Membrane Proteins, Mutation, Neoplasm Metastasis, Organoplatinum Compounds, Proto-Oncogene Proteins, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, GTP Phosphohydrolases, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.